Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Diagnosing Retinitis Pigmentosa by Determining the Ratio of Dolichol Variants in Plasma or Urine

By LabMedica International staff writers
Posted on 28 Oct 2013
A reliable, high-throughput, and cost-effective liquid chromatography-mass spectrometry technique for the quantitative measurement of dolichols in blood plasma or urine can unambiguously discriminate patients with retinitis pigmentosa from asymptotic carriers of the disease genes, and carriers from normal individuals.

Retinitis pigmentosa (RP) is one of the most common forms of inherited retinal degeneration. More...
This disorder is characterized by the progressive loss of photoreceptor cells and may eventually lead to blindness. There are multiple genes that, when mutated, can cause the retinitis pigmentosa phenotype. Among these mutations are the K42E and T206A mutations in the DHDDS (dehydrodolichol diphosphate synthase) gene.

Investigators at the University of Miami (FL, USA) and at Duke University (Durham, NC, USA),using liquid chromatography-mass spectrometry, observed a characteristic shortening of plasma and urinary dolichols in RP patients carrying the K42E and T206A mutations in the DHDDS gene. Dolichol-18 (D18) became the dominant dolichol species in patients compared to dolichol-19 (D19) in normal individuals.

The D18/D19 ratio was calculated and used as an index of dolichol length distribution. K42E/K42E and K42E/T206A patients were found to have significantly higher plasma and urinary D18/D19 ratios than K42E and T206A carriers. The ratios of carriers were significantly higher than normal individuals.

The methodologies and procedures used for dolichol profiling are reliable, high-throughput, and cost-effective. Dolichol profiling, complementary to genotyping, can be readily adapted as a test in the clinic for not only the diagnosis of patients but also identification of carriers with DHDDS or other genetic mutations that may impair dolichol biosynthesis.

"It is our vision that every patient who is affected with an inherited eye disease like RP should have access to a clinician who is knowledgeable about the diseases, as well as to affordable diagnostic testing and counseling," said contributing author Dr. Byron Lam, professor of ophthalmology at the University of Miami. "This diagnostic test is a powerful tool that will help in developing treatments for RP caused by DHDDS mutations."

The study was published in the September 27, 2013, online edition of the Journal of Lipid Research.

Related Links:
University of Miami
Duke University



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.